Novavax, Inc.

Emory University

The Uab Research Foundation (the University of Alabama at Birmingham)

Gale Smith

Peter M Pushko

Michael J Massare

Ye Liu

Kutub Mahmood

Jing-Hui Tian

Yingyun Wu

Rick Bright

Jinyou Zhang

Bin Zhou

Gregory M Glenn

Sarathi Boddapati

Robin A Robinson

Thomas Kort

Erica Shane

Cynthia Oliver

Margaret Nathan

Jason Wong

David Flyer

Yen-Huei Lin

Anushree Herwadkar

Beatrice H Hahn

Richard W Compans

Baozhong Wang

Bin Zhao

Weimin Liu

Louis Fries

Iksung Cho

Margret Nathan

CORONAVIRUS VACCINE FORMULATIONS

Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Methods and compositions for treating respiratory disease

Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towardsinfection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

Methods and compositions for inducing immune responses against

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Corona virus vaccine formulations

Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.

Multivalent influenza nanoparticle vaccines

Coronavirus vaccine formulations

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Modified RSV F proteins and methods of their use

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Vaccine compositions having improved stability and immunogenicity

Methods and compositions for inducing immune responses against Clostridium difficile

Disclosed herein are nanoparticles containing MERS virus proteins in polymer structures, and compositions containing the nanoparticles formulated for administration as immunogenic compositions. Also provided herein are vector constructs encoding the proteins, and host cells containing the vector constructs. The disclosure also includes methods of making the nanoparticles and administering them to vertebrates, including methods of inducing immune responses to MERS that reduce or prevent infection by the virus.

Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods

Growing community of inventors

Gaithersburg, MD, United States of America

Gale Smith